Septerna, Inc. (SEPN)

NASDAQ:
SEPN
| Latest update: Mar 15, 2026, 6:15 PM

Price Chart

$25.14

4.93%
(1 month)

Top Shareholders

Third Rock Ventures LLC
23.29%
RA Capital Management LP
15.62%
Driehaus Capital Holdings LLLP
10.74%
Samsara BioCapital LLC
7.03%
The Goldman Sachs Group, Inc.
6.06%
The Invus Group LLC
4.47%
BlackRock, Inc.
4.02%
BVF, Inc.
3.84%

Sentiment for SEPN

News
Social

Buzz Talk for SEPN

Today

Social Media

General

Stock events for Septerna, Inc. (SEPN)

Septerna, Inc. (SEPN) stock has experienced significant positive movement, increasing over 134% and more than 630% from its 52-week low. Key events impacting the stock price include positive Phase 1 data for SEP-631, analyst upgrades and bullish sentiment, presentations at healthcare conferences, and revenue growth. Over the past 90 days, there has been a net sell-off by insiders, with total sell transactions amounting to approximately $2.58 million, and no buy transactions recorded.

Demand Seasonality affecting Septerna, Inc.’s stock price

There is no information available regarding demand seasonality for Septerna, Inc.'s products and services. As a clinical-stage biotechnology company, its current focus is on drug discovery and development, rather than commercial product sales, which typically exhibit seasonality.

Overview of Septerna, Inc.’s business

Septerna, Inc. is a clinical-stage biotechnology company focused on discovering and developing oral small molecule products targeting G protein-coupled receptors (GPCRs). The company operates in the biotechnology industry and utilizes its Native Complex Platform™ to advance drug candidates across multiple therapeutic areas, including the PTH1R Program (SEP-479) for hypoparathyroidism, SEP-631 for mast cell diseases, TSHR Program for Graves' disease and thyroid eye disease, and programs for metabolic disorders, neurology, women's health, cardiovascular disease, and respiratory disease.

SEPN’s Geographic footprint

Septerna, Inc. is headquartered in South San Francisco, California, United States. The information does not detail a broader international geographic footprint for its operations or product distribution at this clinical stage.

SEPN Corporate Image Assessment

Septerna, Inc. has maintained a largely positive brand reputation in the past year, driven by strong analyst confidence and positive sentiment surrounding its drug discovery platform and lead programs. The company's innovative approach to GPCR oral small molecule drug discovery and promising preclinical and Phase 1 clinical trial results for candidates like SEP-631 have contributed to this positive perception.

Ownership

Septerna, Inc. (SEPN) has a significant institutional ownership presence, with 181 institutional owners and shareholders holding a total of 41,326,296 shares, representing approximately 91.2% of the company. Major institutional and individual owners include RA Capital Management, L.P., Driehaus Capital Management Llc, Third Rock Ventures VI, L.P., Samsara BioCapital, LLC, Goldman Sachs Group Inc, Siren, L.L.C., BlackRock, Inc., BVF Inc/il, Vanguard Group Inc, and Avoro Capital Advisors LLC. Third Rock Ventures VI LP is the largest individual Septerna shareholder, owning 10.43 million shares, representing 23.29% of the company.

FAQ

What is the current stock price of Septerna, Inc.?

As of the latest update, Septerna, Inc.'s stock is trading at $25.14 per share.

What’s happening with Septerna, Inc. stock today?

Today, Septerna, Inc. stock is down by -4.93%, possibly due to news.

What is the market sentiment around Septerna, Inc. stock?

Current sentiment around Septerna, Inc. stock is negative, based on recent news, trading volume, and analyst opinions.

Is Septerna, Inc.'s stock price growing?

Over the past month, Septerna, Inc.'s stock price has decreased by -4.93%.

How can I buy Septerna, Inc. stock?

You can buy Septerna, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol SEPN

Who are the major shareholders of Septerna, Inc. stock?

Major shareholders of Septerna, Inc. include institutions such as Third Rock Ventures LLC (23.29%), RA Capital Management LP (15.62%), Driehaus Capital Holdings LLLP (10.74%) ... , according to the latest filings.